top of page
Dr Sue Snape.png


Clinical Development

Sue is a clinical scientist and development team leader who has helped a number of companies to
progress assets through to licensing or registration.

A Director of Cambridge Drug Development Sciences, Sue was previously VP of program
management at Vectura, leading two fully-integrated late-stage program teams developing drug-
device combination products to treat severe adult asthma and paediatric asthma. Her particular
areas of expertise and interest are in drug repurposing and Sue has been instrumental in achieving
proof-of-concept for several products, including glycopyrronium for the treatment of asthma and
COPD (marketed as Breezehaler/Neohaler), and has played a key role in licensing assets to
companies including Novartis, Mundipharma, Teijin and Roche.

Sue is originally a biochemist, graduating from the University of York before working for the Medical
Research Council as a researcher in disorders of iron metabolism. She gained a PhD from this work
whilst working at Northwick Park and Kings College Hospitals in London and has an MBA from the
University of Cambridge.

bottom of page